Beacon Therapeutics

Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025

Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry Laru-zova was generally well-tolerated by DAWN participants at 6 months. 6 May 2025 -- London, UK and Massachusetts, US -- Beacon Therapeutics Holdings Limited, a leading clinical-stage biotechnology company with a mission to save and restore the vision...
14193 NW 119th Terrace,
 Suite #20,
 Alachua, Florida 32615, US

+1 386 4622204